- Home
- SNSE vs BOLT Comparison
SNSE vs BOLT Comparison
Compare SNSE & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNSE | BOLT |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.9M | 10.5M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SNSE | BOLT |
|---|---|---|
| Price | $11.81 | $6.67 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $72.50 | $34.00 |
| AVG Volume (30 Days) | ★ 71.0K | 25.0K |
| Earning Date | 11-14-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,195,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.00 | $4.41 |
| 52 Week High | $18.35 | $11.70 |
Technical Indicators
Market Signals| Indicator | SNSE | BOLT |
|---|---|---|
| Relative Strength Index (RSI) | 65.33 | 71.18 |
| Support Level | $11.14 | $5.61 |
| Resistance Level | $11.35 | $6.09 |
| Average True Range (ATR) | 0.98 | 0.33 |
| MACD | 0.24 | 0.07 |
| Stochastic Oscillator | 97.39 | 92.09 |
Price Performance
Historical ComparisonAbout SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.